



Joint working executive summary

Project title	Barts Health and Sanofi Joint Working Project – Improving experience and outcomes for people with recent ACS admission and raised cholesterol in Barts Health
Partner organisation/s	Barts Health NHS Trust Sanofi Pharmaceuticals
Project rationale	<p>Cardiovascular disease is the most common cause of death in the UK, and is a major cause of illness, disability and poor quality of life. Risk of CHD is directly related to blood cholesterol levels, and lowering cholesterol can reduce the risk of heart disease, stroke and peripheral arterial disease. NICE guidance exists to support people with raised cholesterol and practitioners in identify, risk stratify and manage cholesterol levels. However, challenges remain in supporting people with raised cholesterol to benefit from the interventions available to reduce blood cholesterol including drugs, physical activity and dietary changes.</p> <p>The Barts Heart Centre (BHC) was formed following the successful recent transition of services from the London Chest Hospital and The Heart Hospital. The Barts Heart Centre is a unique new hub including an academic health sciences network, serving a primary population of six million patients across north and east London, south and west Hertfordshire, south Bedfordshire and south west and mid-Essex. It is the UK’s largest heart centre and will treat approximately 80,000 patients a year. The Centre’s state-of-the-art facilities include 10 theatres, 10 catheter labs, 250 general cardiac beds and 58 critical care beds.</p> <p>This is a new service aiming to developing a pathway to manage high risk ACS patients, who are recognized as being at the highest risk for further events. This service will formalize the process for identifying and treating high risk CVD patients post ACS through the appointment of a dedicated pharmacist.</p>
Project period	Anticipated finish date for this project is Quarter 2 2020.

Project objectives	<p>Expected Benefits for Patients and the NHS By developing this service the aim is to increase the proportion of patients with recent ACS receiving appropriate care in line with local and national guidelines, especially in relation to lipid lowering therapy. In turn, this is expected to lead to improved patient outcomes, reduced burden on the local health economy and serve to deliver innovation to the localities served by Barts Health.</p> <p>Expected benefits for Sanofi Improving care for patients with hypercholesteraemia is the principal benefit. Working with a key Cardiac Centre in London will provide opportunity for partnership working and improved reputation with the NHS. Improvement in care of patients at high risk due to hypercholesteraemia in line with NICE recommendations may result in the increased use of appropriate medicines, including Sanofi medicines.</p>
Contact details	<p>NHS: Dr Riyaz Patel, St Bartholomew's Hospital, West Smithfield, London. EC1A 7BE. Tel – 0203 765 8640 (Sec)</p> <p>Sanofi: Jessamy Baird Director of Patient Access Sanofi Pharmaceuticals 1 Onslow Street Guildford Surrey. GU1 4SY Tel Email - GB-PatientAccess@sanofi.com</p>